[1] 2021 Alzheimer's disease facts and figures. Alzheimers Dement. 2021 Mar;17(3): 327-406. )
[2] GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health, 2022; 7, e105−25. doi:  10.1016/S2468-2667(21)00249-8
[3] Jia LF, Du YF, Chu L, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. Lancet Public Health, 2020; 5, e661−71. doi:  10.1016/S2468-2667(20)30185-7
[4] Rabin LA, Smart CM, Amariglio RE. Subjective cognitive decline in preclinical Alzheimer's disease. Annu Rev Clin Psychol, 2017; 13, 369−96. doi:  10.1146/annurev-clinpsy-032816-045136
[5] Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. JAMA, 2014; 312, 2551−61. doi:  10.1001/jama.2014.13806
[6] Liu XY, Li L, Xiao JQ, et al. Cognitive training in older adults with mild cognitive impairment. Biomed Environ Sci, 2016; 29, 356−64.
[7] Mendoza-Holgado C, Lopez-Espuela F, Moran JM, et al. A pilot test for a one-year cognitive training intervention in elderly adults with mild cognitive impairment. Biomed Environ Sci, 2020; 33, 796−802.
[8] Pu LN, Pan DG, Wang HH, et al. A predictive model for the risk of cognitive impairment in community middle-aged and older adults. Asian J Psychiatr, 2023; 79, 103380. doi:  10.1016/j.ajp.2022.103380
[9] Tran J, Nimojan T, Saripella A, et al. Rapid cognitive assessment tools for screening of mild cognitive impairment in the preoperative setting: a systematic review and meta-analysis. J Clin Anesth, 2022; 78, 110682. doi:  10.1016/j.jclinane.2022.110682
[10] Meng XN, Li XC, Cao ML, et al. Summarizing attributable factors and evaluating risk of bias of Mendelian randomization studies for Alzheimer's dementia and cognitive status: a systematic review and meta-analysis. Syst Rev, 2025; 14, 61. doi:  10.1186/s13643-025-02792-5
[11] Davies G, Lam M, Harris SE, et al. Study of 300, 486 individuals identifies 148 independent genetic loci influencing general cognitive function. Nat Commun, 2018; 9, 2098. doi:  10.1038/s41467-018-04362-x
[12] Lee JJ, Wedow R, Okbay A, et al. Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. Nat Genet, 2018; 50, 1112−21. doi:  10.1038/s41588-018-0147-3
[13] Ye YQ, Zhang Z, Liu YM, et al. A multi-omics perspective of quantitative trait loci in precision medicine. Trends Genet, 2020; 36, 318−36. doi:  10.1016/j.tig.2020.01.009
[14] Reily C, Stewart TJ, Renfrow MB, et al. Glycosylation in health and disease. Nat Rev Nephrol, 2019; 15, 346−66. doi:  10.1038/s41581-019-0129-4
[15] Wang W. Glycomedicine: the current state of the art. Engineering, 2022; 26, 12−5.
[16] Liu D, Li QH, Zhang XY, et al. Systematic review: immunoglobulin G N-Glycans as next-generation diagnostic biomarkers for common chronic diseases. OMICS, 2019; 23, 607−14. doi:  10.1089/omi.2019.0032
[17] Liu D, Zhao ZY, Wang AX, et al. Ischemic stroke is associated with the pro-inflammatory potential of N-glycosylated immunoglobulin G. J Neuroinflammation, 2018; 15, 123. doi:  10.1186/s12974-018-1161-1
[18] Yu XW, Wang YX, Kristic J, et al. Profiling IgG N-glycans as potential biomarker of chronological and biological ages: a community-based study in a Han Chinese population. Medicine, 2016; 95, e4112. doi:  10.1097/MD.0000000000004112
[19] Zhang XY, Yuan H, Lyu JH, et al. Association of dementia with immunoglobulin G N-glycans in a Chinese Han Population. NPJ Aging, 2021; 7, 3. doi:  10.1038/s41514-021-00055-w
[20] Wang M, Chen XY, Tang ZY, et al. Association between immunoglobulin G N-glycosylation and vascular cognitive impairment in a sample with atherosclerosis: a case-control study. Front Aging Neurosci, 2022; 14, 823468. doi:  10.3389/fnagi.2022.823468
[21] Meng XN, Liu D, Cao ML, et al. Potentially causal association between immunoglobulin G N-glycans and cardiometabolic diseases: bidirectional two-sample Mendelian randomization study. Int J Biol Macromol, 2024; 279, 135125. doi:  10.1016/j.ijbiomac.2024.135125
[22] Meng XN, Cao WJ, Liu D, et al. Bidirectional causality between immunoglobulin G N-glycosylation and metabolic traits: a Mendelian randomization study. Engineering, 2023; 26, 74−88. doi:  10.1016/j.eng.2022.11.004
[23] Davies NM, Holmes MV, Smith GD. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ, 2018; 362, k601.
[24] Zheng J, Haberland V, Baird D, et al. Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. Nat Genet, 2020; 52, 1122−31. doi:  10.1038/s41588-020-0682-6
[25] Zuber V, Grinberg NF, Gill D, et al. Combining evidence from Mendelian randomization and colocalization: review and comparison of approaches. Am J Hum Genet, 2022; 109, 767−82. doi:  10.1016/j.ajhg.2022.04.001
[26] Kong JT, Wang MX, Zhang XZ, et al. Role of the gut-brain axis in chronotype-driven Alzheimer's disease: a Mendelian randomization study. Biomed Environ Sci, 2025; 38, 519−24.
[27] Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol, 2013; 37, 658−65. doi:  10.1002/gepi.21758
[28] Sanderson E. Multivariable Mendelian randomization and mediation. Cold Spring Harb Perspect Med, 2021; 11, a038984. doi:  10.1101/cshperspect.a038984
[29] Sun BB, Maranville JC, Peters JE, et al. Genomic atlas of the human plasma proteome. Nature, 2018; 558, 73−9. doi:  10.1038/s41586-018-0175-2
[30] Folkersen L, Fauman E, Sabater-Lleal M, et al. Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease. PLoS Genet, 2017; 13, e1006706. doi:  10.1371/journal.pgen.1006706
[31] Suhre K, Arnold M, Bhagwat AM, et al. Connecting genetic risk to disease end points through the human blood plasma proteome. Nat Commun, 2017; 8, 14357. doi:  10.1038/ncomms14357
[32] Shen X, Klarić L, Sharapov S, et al. Multivariate discovery and replication of five novel loci associated with Immunoglobulin G N-glycosylation. Nat Commun, 2017; 8, 447. doi:  10.1038/s41467-017-00453-3
[33] Nakahara J, Kanekura K, Nawa M, et al. Abnormal expression of TIP30 and arrested nucleocytoplasmic transport within oligodendrocyte precursor cells in multiple sclerosis. J Clin Invest, 2009; 119, 169−81.
[34] Manjaly ZM, Harrison NA, Critchley HD, et al. Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis. J Neurol Neurosurg Psychiatry, 2019; 90, 642−51. doi:  10.1136/jnnp-2018-320050
[35] Zhan SS, Sandbrink R, Beyreuther K, et al. APP with Kunitz type protease inhibitor domain (KPI) correlates with neuritic plaque density but not with cortical synaptophysin immunoreactivity in Alzheimer's disease and non-demented aged subjects: a multifactorial analysis. Clin Neuropathol, 1995; 14, 142−9.
[36] Mitsi V, Terzi D, Purushothaman I, et al. RGS9-2--controlled adaptations in the striatum determine the onset of action and efficacy of antidepressants in neuropathic pain states. Proc Natl Acad Sci U S A, 2015; 112, E5088-97.
[37] Eising E, Carrion-Castillo A, Vino A, et al. A set of regulatory genes co-expressed in embryonic human brain is implicated in disrupted speech development. Mol Psychiatry, 2019; 24, 1065−78. doi:  10.1038/s41380-018-0020-x
[38] Liu HY, Yang YD, Ge YL, et al. TERC promotes cellular inflammatory response independent of telomerase. Nucleic Acids Res, 2019; 47, 8084−95. doi:  10.1093/nar/gkz584